{
  "docId": "019de073-b144-743c-94c4-bc5a80eb44df",
  "docSlug": "9540d42c57dd536e8cb82c97bd211004",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 50 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 27,
  "pageCount": 50,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Highlights the validation of the product by a major industry player (Bayer) and the financial terms of the deal.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b144-743c-94c4-bc5a80eb44df/27",
  "deckHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df",
  "deckJsonHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df.json",
  "deckAnchorHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.14,
        "w": 0.14,
        "x": 0.07,
        "y": 0.54
      },
      "kind": "image",
      "text": "Bayer logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "197a2136-fa14-4d2e-9db7-f6ffafd9ee92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.43,
        "y": 0.15
      },
      "kind": "list",
      "text": "Bayer received the right to obtain exclusive US rights to commercialize the product, following completion of the pivotal clinical trial if Bayer, in its sole discretion, pays Daré $20 million. Daré may receive up to $310 million in commercial milestone payments, plus double-digit, tiered royalties on net sales. Bayer supports the development and regulatory process by providing up to two full-time equivalents (internal experts) in an advisory capacity, which gives Daré access to their global manufacturing, regulatory, medical and commercial expertise.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8e73caa-b3ee-42f2-a05c-11f5a4ed6031",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "January 2020 - Bayer, which markets the $1 billion Mirena contraceptive franchise, and Daré announced the execution of a license agreement under which Bayer may commercialize Ovaprene investigational contraceptive in the US once approved by FDA.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87a2fca8-126b-4bd1-96d3-009b6048e532",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.22,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Mirena is the #1 prescribed IUD in the U.S.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88c3bf52-1e7b-4642-ab52-37c6337a5341",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "We believe the licensing agreement with Bayer is validation of our broader corporate strategy and confirmation of Ovaprene's market potential, if approved, as the first monthly non-hormonal contraceptive product in the US market.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3af736e-92d2-4263-9a2f-01cec2125deb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "* https://www.mirena-us.com/; supported by 2014-2016 SHS data. 1.https://ir.darebioscience.com/news-releases/news-release-details/bayer-and-dare-bioscience-announce-exclusive-licensing-agreement",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7acc8983-decd-46c5-a428-fd7d6253cb9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.64,
        "x": 0.18,
        "y": 0.03
      },
      "kind": "title",
      "text": "Ovaprene - Commercial License Agreement with Bayer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec84bd2b-baca-407e-bb0e-1abfa149c0ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a28fba1a-0cd5-452c-ba3d-8fb388474349",
      "evidence": "list/bullet: Bayer received the right to obtain exclusive US rights to commercialize the product, following completion of the pivotal clinical trial if Bayer, in its sole discretion, pays Daré $20 million.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}